blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3516060

EP3516060 - ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.05.2022
Database last updated on 18.09.2024
FormerThe patent has been granted
Status updated on  18.06.2021
FormerGrant of patent is intended
Status updated on  23.03.2021
FormerExamination is in progress
Status updated on  14.08.2020
FormerRequest for examination was made
Status updated on  28.06.2019
FormerThe international publication has been made
Status updated on  30.03.2018
Formerunknown
Status updated on  20.10.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden / NL
[2019/31]
Inventor(s)01 / VAN DIEPEN, Hester Catharina
c/o ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden / NL
02 / TURUNEN, Janne Juha
c/o ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden / NL
03 / CHAN, Hee Lam
c/o ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden / NL
 [2019/31]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2019/31]
Application number, filing date17781030.622.09.2017
[2019/31]
WO2017EP74133
Priority number, dateGB2016001620223.09.2016         Original published format: GB 201616202
[2019/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018055134
Date:29.03.2018
Language:EN
[2018/13]
Type: A1 Application with search report 
No.:EP3516060
Date:31.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 29.03.2018 takes the place of the publication of the European patent application.
[2019/31]
Type: B1 Patent specification 
No.:EP3516060
Date:21.07.2021
Language:EN
[2021/29]
Search report(s)International search report - published on:EP29.03.2018
ClassificationIPC:C12N15/113, A61K31/7088, A61K31/712, A61P27/02
[2021/12]
CPC:
C12N15/113 (EP,IL,KR,US); A61K31/7088 (EP,IL,KR,US); A61K31/712 (EP,IL,US);
A61K48/00 (IL,KR); A61P27/02 (EP,IL,KR); C12N15/86 (IL,KR);
C12N2310/11 (IL,KR,US); C12N2310/14 (IL,KR); C12N2310/315 (IL,KR);
C12N2310/321 (IL,KR,US) (-)
Former IPC [2019/31]C12N15/113, A61K48/00, A61K31/7088
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/31]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ANTISENSE-OLIGONUKLEOTIDE ZUR BEHANDLUNG VON AUGENERKRANKUNGEN[2021/12]
English:ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE[2019/31]
French:OLIGONUCLÉOTIDES ANTISENS POUR LE TRAITEMENT DE MALADIES OCULAIRES[2021/12]
Former [2019/31]ANTISENSE-OLIGONUKLEOTIDE ZUR BEHANDLUNG VON AUGENERKRANKUNG
Former [2019/31]OLIGONUCLÉOTIDES ANTISENS POUR LE TRAITEMENT D'UNE MALADIE OCULAIRE
Entry into regional phase15.04.2019National basic fee paid 
15.04.2019Designation fee(s) paid 
15.04.2019Examination fee paid 
Examination procedure15.04.2019Examination requested  [2019/31]
15.04.2019Date on which the examining division has become responsible
25.09.2019Amendment by applicant (claims and/or description)
13.08.2020Despatch of a communication from the examining division (Time limit: M04)
20.10.2020Reply to a communication from the examining division
23.03.2021Communication of intention to grant the patent
09.06.2021Fee for grant paid
09.06.2021Fee for publishing/printing paid
09.06.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21185745.3  / EP3985117
Opposition(s)22.04.2022No opposition filed within time limit [2022/26]
Fees paidRenewal fee
13.09.2019Renewal fee patent year 03
14.09.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.09.2017
AL21.07.2021
CY21.07.2021
CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MK21.07.2021
MT21.07.2021
RO21.07.2021
RS21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
[2024/42]
Former [2024/23]HU22.09.2017
AL21.07.2021
CY21.07.2021
CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
MK21.07.2021
RO21.07.2021
RS21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
Former [2023/33]HU22.09.2017
AL21.07.2021
CY21.07.2021
CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
RO21.07.2021
RS21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
Former [2023/30]AL21.07.2021
CY21.07.2021
CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
RO21.07.2021
RS21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
Former [2022/29]AL21.07.2021
CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
RO21.07.2021
RS21.07.2021
SI21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
Former [2022/25]CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
RO21.07.2021
RS21.07.2021
SK21.07.2021
SM21.07.2021
BG21.10.2021
Former [2022/24]CZ21.07.2021
EE21.07.2021
HR21.07.2021
LT21.07.2021
LV21.07.2021
RO21.07.2021
RS21.07.2021
SK21.07.2021
BG21.10.2021
Former [2022/12]HR21.07.2021
LT21.07.2021
LV21.07.2021
RS21.07.2021
BG21.10.2021
Former [2022/09]LT21.07.2021
RS21.07.2021
BG21.10.2021
Former [2022/08]LT21.07.2021
BG21.10.2021
Cited inInternational search[A]WO2012151324  (ISIS PHARMACEUTICALS INC [US], et al) [A] 1-20* claims 1-9 *;
 [XA]WO2015134812  (EDITAS MEDICINE INC [US]) [X] 1 * sequences 460, 18, 115 * [A] 2-20;
 [I]WO2016005514  (STICHTING KATHOLIEKE UNIV [NL]) [I] 2-20 * page 42, line 23 - line 25; claims 15, 16, 21, 22; sequences 15, 16 *;
 [A]  - LENASSI EVA ET AL, "The effect of the common c.2299delG mutation inUSH2Aon RNA splicing", EXPERIMENTAL EYE RESEARCH, (20140304), vol. 122, doi:10.1016/J.EXER.2014.02.018, ISSN 0014-4835, pages 9 - 12, XP028659806 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.exer.2014.02.018
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.